Shopping Cart 0
Cart Subtotal
USD 0

KOL Perspectives: Adaptive Trial Designs in IBD

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

KOL Perspectives: Adaptive Trial Designs in IBD

Summary

This KOL Insight briefing focuses on KOLs views of Adaptive trial designs in IBD.

Questions topics-

- Current challenges in IBD clinical trials

- Adaptive Phase II/III trial designs

- Guselkumab's Phase II/III trial in Crohn's disease

- Novel clinical trials in IBD

Key Highlights

- Most KOLs highlighted that recruitment is the greatest challenge in IBD clinical trials, both across Crohn's disease & UC

- Most KOLs flagged Phase II/III trials could accelerate development, but may limit ability to analyze data & adapt trial design

- Most KOLs cited 8-12 weeks as being the minimum duration of a Phase II trial in IBD, with open-label extensions favored by all KOLs.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our IBD key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during July 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on Adaptive trial designs in IBD

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Adaptive, trial, IL-23, guselkumab


Companies

Janssen

AbbVie

Gilead

KOL Perspectives: Adaptive Trial Designs in IBD

Summary

This KOL Insight briefing focuses on KOLs views of Adaptive trial designs in IBD.

Questions topics-

- Current challenges in IBD clinical trials

- Adaptive Phase II/III trial designs

- Guselkumab's Phase II/III trial in Crohn's disease

- Novel clinical trials in IBD

Key Highlights

- Most KOLs highlighted that recruitment is the greatest challenge in IBD clinical trials, both across Crohn's disease & UC

- Most KOLs flagged Phase II/III trials could accelerate development, but may limit ability to analyze data & adapt trial design

- Most KOLs cited 8-12 weeks as being the minimum duration of a Phase II trial in IBD, with open-label extensions favored by all KOLs.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our IBD key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during July 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on Adaptive trial designs in IBD

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Adaptive, trial, IL-23, guselkumab


Companies

Janssen

AbbVie

Gilead